Tayo Sanders II

Tayo Sanders II is a distinguished scientist and biotech investor with a strong foundation in materials science and biomedical engineering. His academic excellence is highlighted by being a Goldwater Scholar and a Rhodes Scholar, leading to a Ph.D. from the University of Oxford. He has extensive research experience in nanotechnology, with numerous publications and presentations, including research conducted at the University of Strasbourg in France. ac+2

As a co-founder and business leader, Tayo has a proven track record in the biotech and deep tech sectors. He co-founded Stealth and Arrowpoint Labs, a venture creation and advisory firm focused on regional innovation ecosystems. In his role as Chief Business Officer at Singular Immune, he drives strategic partnerships and business development for in vivo cell engineering, working on innovative protein-based approaches for CAR conversion. in-vivo-engineering+2

Tayo possesses significant expertise in venture capital and investment, particularly in identifying and supporting groundbreaking biotech and industrial technologies. While at Anzu Partners, he led due diligence on over 15 companies, deploying more than $130 million in capital and contributing to an 8x return on an early investment. He has also served as an investor and board observer for companies like CytoTronics, Excision BioTherapeutics, Nature's Toolbox, Inc. (NTx), and Codetta Bio™. tedco+2

Beyond his direct investment roles, Tayo has been instrumental in fostering innovation ecosystems. He directed the Southern Research Venture Studio, focusing on commercializing early-stage life sciences technology and guiding drug programs through rigorous selection processes. His work in this area includes advancing therapies for cancer, chronic pain, and other diseases, demonstrating his commitment to bringing new therapeutic products to market. southernresearch+2